The World Health Organization (WHO) Thursday urged governments to prioritise COVID-19 recognition, rehabilitation, and research, as well as the collecting of standardised data on Long COVID and suggested that the term “Post COVID-19 condition” be used to describe persons living with Long COVID.
Months after the acute infection, a considerable majority of persons diagnosed with COVID-19 develop long-term symptoms such as weariness, dyspnea, and neurological problems.
The evidence for this illness, on the other hand, is poor and based on small patient cohorts with short follow-up.
The establishment of a core outcome set (COS) for this illness is critical in order to optimise and standardise clinical data collecting and reporting across studies (particularly clinical trials) and clinical practice, WHO said in a press release.
With this in mind, clinical research communities and people living with Post COVID-19 have banded together to address the worldwide healthcare catastrophe that is looming.
An international group of experts in COS development and Post COVID-19 Condition research and clinical practice have developed a programme of research together with WHO (World Health Organisation), ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium), and patient partners to develop a Post COVID-19 Condition COS.
In two phases, the Post-COVID Condition Core Outcomes project will interview people living with Post-COVID-19 conditions, assess what outcomes matter, and develop a plan.
The first phase will concentrate on determining what outcomes should be measured, while the second will concentrate on determining how to measure these results.
The first phase (what outcomes to measure) is expected to be completed in the summer of 2021, followed by the second part (how to evaluate these outcomes) in the summer of 2022.
This project has been registered on COMET’s COS registry and adheres to the COMET (Core Outcome Measures in Effectiveness Trials) Initiative’s requirements.
This plan is being widely publicised in its early phases to inform the research and patient communities, potentially preventing duplication of effort, and to inform researchers planning studies, particularly clinical trials, and physicians about the expected timeline for these suggestions.